SGLT2 Inhibitors Market Revenue Grows at a CAGR of 7.05%.

Introduction

Straits Research today released its highly anticipated report, “Global SGLT2 Inhibitors Market Size & Outlook, 2026-2034”. The market size is valued at USD 13.43 billion in 2025 and is projected to expand to USD 24.71 billion by 2034, registering a compound annual growth rate (CAGR) of 7.05%.

Market Dynamics

The growth of the global SGLT2 inhibitors market is primarily driven by the rising prevalence of type 2 diabetes and cardiovascular diseases worldwide. SGLT2 inhibitors have gained strong clinical acceptance due to their proven ability to lower blood glucose levels while also providing additional benefits such as weight reduction, blood pressure control, and a lower risk of heart failure and kidney disease. Increasing awareness among healthcare professionals about these multi-organ benefits has led to their inclusion in international diabetes and cardiology treatment guidelines, supporting market growth. Furthermore, the growing aging population and sedentary lifestyles continue to increase the diabetic patient pool, thereby driving demand for SGLT2 inhibitor therapies.

Despite strong growth potential, the market faces a key restraint in the form of high treatment costs and safety-related concerns. Branded SGLT2 inhibitors remain expensive in many regions, limiting access for patients in low and middle-income countries. In addition, side effects such as urinary tract infections, dehydration, and rare cases of diabetic ketoacidosis have raised concerns among patients and physicians, which can restrict wider adoption and long-term use. On the other hand, the market presents a substantial opportunity through expanding indications beyond diabetes management. Increasing clinical evidence supporting the use of SGLT2 inhibitors in chronic kidney disease and heart failure patients, including non diabetic populations, is opening new revenue streams.

Market Highlights

• Drug: The Ertugliflozin segment is expected to register the fastest CAGR of 7.85% during the forecast period.
• Indication: The type 2 diabetes segment dominated the market in 2025, with a revenue share of 69.53%.
• Distribution Channel: The hospital pharmacies segment dominated the market in 2025, accounting for 51.06% market share in 2025. 
• Regional Insights: North America dominated the market, accounting for 41.02% of market share in 2025, owing to rapid regulatory approvals by authorities such as the U.S. FDA, and increasing prescription rates by endocrinologists and cardiologists.

Competitive Players

1. Arena Pharmaceuticals
2. Astellas Pharma
3. AstraZeneca
4. Boehringer Ingelheim
5. Chong Kun Dang
6. Cipla Ltd.
7. Dr Reddy's Laboratories
8. Eli Lilly and Company
9. Glenmark Pharma
10. Janssen Pharmaceuticals
11. Lupin Ltd.
12. Merck & Co. Inc.
13. Otsuka Pharmaceutical
14. Sumitomo Pharma
15. Sun Pharmaceutical Ltd.
16. Taisho Pharma
17. Torrent Pharma
18. Zydus Lifesciences
19. Others

Recent Developments

• September 2025: AstraZeneca launched the online platform designed to create a convenient way for eligible patients to access prescriptions for FARXIGA (dapaglifozin) and AIRSUPRA.

Segmentation

1. By Drug (2026-2034)
   1. Canagliflozin
   2. Dapagliflozin
   3. Empagliflozin
   4. Ertugliflozin
   5. Ipragliflozin
   6. Sotagliflozin
   7. Others
2. By Indication (2026-2034)
   1. Type 2 Diabetes
   2. Cardiovascular
   3. Chronic Kidney Disease 
   4. Weight Management
   5. Others
3. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Drug Stores & Retail Pharmacies
   3. Online Pharmacies
4. By Region (2026-2034)
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Latin America
   5. The Middle East and Africa